LEADER 01299nam  2200373Ka 450 
001 9910696645303321
005 20080610143458.0
035   $a(CKB)5470000002380409
035   $a(OCoLC)231631530
035   $a(EXLCZ)995470000002380409
100   $a20080610d2002      ua             0
101 0 $aeng
181   $ctxt$2rdacontent
182   $cc$2rdamedia
183   $acr$2rdacarrier
200 10$aGeneric drug industry dynamics$b[electronic resource] /$fDavid Reiffen and Michael R. Ward
210  1$a[Washington, D.C.] :$c[Bureau of Economics, U.S. Federal Trade Commission],$d[2002]
215   $a53 pages $cdigital, PDF file
225 1 $a[Working paper ;$vno. 248]
300   $aTitle from title screen (viewed on June 10, 2008).
300   $a"February, 2002."
606   $aGeneric drugs$xEconomic aspects$zUnited States
606   $aPharmaceutical industry$zUnited States
615  0$aGeneric drugs$xEconomic aspects
615  0$aPharmaceutical industry
700   $aReiffen$b David A$01385696
701   $aWard$b Michael R$01385698
712 02$aUnited States.$bFederal Trade Commission.$bBureau of Economics.
801  0$bGPO
801  1$bGPO
906   $aBOOK
912   $a9910696645303321
996   $aGeneric drug industry dynamics$93449671
997   $aUNINA